René González

59.3k total citations · 1 hit paper
189 papers, 9.2k citations indexed

About

René González is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, René González has authored 189 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Oncology, 100 papers in Molecular Biology and 58 papers in Immunology. Recurrent topics in René González's work include Melanoma and MAPK Pathways (77 papers), CAR-T cell therapy research (60 papers) and Cutaneous Melanoma Detection and Management (50 papers). René González is often cited by papers focused on Melanoma and MAPK Pathways (77 papers), CAR-T cell therapy research (60 papers) and Cutaneous Melanoma Detection and Management (50 papers). René González collaborates with scholars based in United States, Australia and Germany. René González's co-authors include Karl D. Lewis, William A. Robinson, Dirk Schadendorf, F. Stephen Hodi, Martin D. McCarter, Christopher D. Lao, Steven O’Day, Piotr Rutkowski, Jedd D. Wolchok and C. Lance Cowey and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

René González

184 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

2018 1.0k citations F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
René González United States	48	6.6k	4.4k	2.6k	1.2k	729	189	9.2k
Helen Gogas Greece	49	6.5k 1.0×	3.8k 0.9×	2.2k 0.8×	1.1k 1.0×	1.1k 1.6×	330	9.2k
Anna C. Pavlick United States	50	5.8k 0.9×	4.7k 1.1×	2.2k 0.8×	1.3k 1.1×	1.2k 1.6×	219	8.9k
Paola Queirolo Italy	44	5.3k 0.8×	3.0k 0.7×	2.5k 0.9×	951 0.8×	662 0.9×	233	7.3k
Karl D. Lewis United States	41	4.9k 0.7×	4.0k 0.9×	1.5k 0.6×	813 0.7×	525 0.7×	177	7.8k
Jacob Schachter Israel	47	6.5k 1.0×	3.0k 0.7×	3.0k 1.1×	857 0.7×	748 1.0×	189	8.4k
Laurent Mortier France	43	4.7k 0.7×	3.4k 0.8×	1.7k 0.6×	1.4k 1.2×	564 0.8×	307	8.1k
Alessandro Testori Italy	53	6.0k 0.9×	3.6k 0.8×	2.6k 1.0×	893 0.8×	697 1.0×	213	9.4k
Harriet M. Kluger United States	59	7.7k 1.2×	5.1k 1.2×	3.5k 1.3×	3.1k 2.7×	1.3k 1.8×	319	12.4k
Christian U. Blank Netherlands	53	10.6k 1.6×	5.0k 1.1×	6.6k 2.5×	2.0k 1.7×	1.2k 1.6×	272	14.7k
Alexander M. Menzies Australia	55	9.8k 1.5×	5.1k 1.2×	3.2k 1.2×	2.5k 2.1×	1.2k 1.7×	330	12.6k

Countries citing papers authored by René González

Since Specialization

Citations

This map shows the geographic impact of René González's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by René González with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites René González more than expected).

Fields of papers citing papers by René González

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by René González. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by René González. The network helps show where René González may publish in the future.

Co-authorship network of co-authors of René González

This figure shows the co-authorship network connecting the top 25 collaborators of René González. A scholar is included among the top collaborators of René González based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with René González. René González is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2023). Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.. Journal of Clinical Oncology. 41(16_suppl). 9542–9542.

Zheng, Qiao, Jingli Xu, Darrell R. Fisher, René González, & Yubin Miao. (2023). Introduction of a Polyethylene Glycol Linker Improves Uptake of 67Cu-NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide in Melanoma. Cancers. 15(10). 2755–2755. 5 indexed citations

Xu, Jingli, Fabio Gallazzi, Darrell R. Fisher, René González, & Yubin Miao. (2021). The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of ⁶⁷ Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Cancer Biotherapy and Radiopharmaceuticals. 37(1). 47–55. 4 indexed citations

Xu, Jingli, Qiao Zheng, René González, & Yubin Miao. (2020). Facile preparation of a novel Ga-67-labeled NODAGA-conjugated lactam-cyclized alpha-MSH peptide at room temperature for melanoma targeting. Bioorganic & Medicinal Chemistry Letters. 30(24). 127627–127627. 2 indexed citations

Ribas, Antoni, Adil Daud, Anna C. Pavlick, et al.. (2019). Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma. Clinical Cancer Research. 26(1). 46–53. 30 indexed citations

Xu, Jingli, Jianquan Yang, René González, Darrell R. Fisher, & Yubin Miao. (2019). Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide. Cancer Biotherapy and Radiopharmaceuticals. 34(9). 597–603. 14 indexed citations

Yang, Jianquan, Jingli Xu, René González, et al.. (2018). ⁶⁸ Ga-DOTA-GGNle-CycMSH _hex targets the melanocortin-1 receptor for melanoma imaging. Science Translational Medicine. 10(466). 39 indexed citations

Hwu, Patrick, Omid Hamid, René González, et al.. (2016). Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Annals of Oncology. 27. vi380–vi380. 26 indexed citations

Ribas, Antoni, René González, Joseph J. Drabick, et al.. (2016). Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma. Annals of Oncology. 27. vi365–vi365. 5 indexed citations

10.

Carvajal, Richard D., Donald P. Lawrence, Jeffrey S. Weber, et al.. (2015). Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research. 21(10). 2289–2296. 97 indexed citations

11.

Gerami, Pedram, Robert W. Cook, Maria C. Russell, et al.. (2015). Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. Journal of the American Academy of Dermatology. 72(5). 780–785.e3. 116 indexed citations

12.

Ribas, Antoni, René González, Anna C. Pavlick, et al.. (2014). Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. The Lancet Oncology. 15(9). 954–965. 201 indexed citations

13.

Karimkhani, Chanté, René González, & Robert P. Dellavalle. (2014). A Review of Novel Therapies for Melanoma. American Journal of Clinical Dermatology. 15(4). 323–337. 50 indexed citations

14.

Kim, Kevin B., Richard Kefford, Anna C. Pavlick, et al.. (2012). Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology. 31(4). 482–489. 356 indexed citations

15.

Kudchadkar, Ragini R., Karl D. Lewis, & René González. (2012). Advances in the Treatment of Basal Cell Carcinoma: Hedgehog Inhibitors. Seminars in Oncology. 39(2). 139–144. 14 indexed citations

16.

Amaria, Rodabe N., Karl D. Lewis, & René González. (2011). Therapeutic options in cutaneous melanoma: latest developments. Therapeutic Advances in Medical Oncology. 3(5). 245–251. 7 indexed citations

17.

Kavanagh, Brian D., Tracey E. Schefter, René González, et al.. (2011). Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiation Oncology. 6(1). 34–34. 114 indexed citations

18.

Kavanagh, Brian D., Tracey E. Schefter, René González, et al.. (2010). Stereotactic Body Radiation Therapy for Melanoma and Renal Cell Carcinoma: Impact of Single Fraction Equivalent Dose on Local Control. International Journal of Radiation Oncology*Biology*Physics. 78(3). S190–S191. 10 indexed citations

19.

Hersey, Peter, Jeffrey A. Sosman, Steven O’Day, et al.. (2010). A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α_vβ₃, ± dacarbazine in patients with stage IV metastatic melanoma. Cancer. 116(6). 1526–1534. 150 indexed citations

20.

Gibbs, Peter, et al.. (2001). Medical management of cutaneous malignancies. Clinics in Dermatology. 19(3). 298–304. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact